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INTRODUCTION:  Choroidal  melanoma  is  the  most  common  primary  intraocular  malignant  tumour  and
the  second  most  common  type  of  primary  malignant  melanoma  in the body.  Biologically,  cutaneuous
and  ocular  melanoma  may  be  considered  different,  in terms  of  both  metastatic  diffusion  and metastatic
latency.  The  principal  target  organ  for metastasis  of  the  ocular  melanoma  is the  liver.This  distinctive
behaviour  is also sustained  by different  metastatic  latency,  as  some  patients  present  with  metastatic
ocular  melanoma  several  years  after the treatment  of the  primary  tumor.
PRESENTATION  OF  CASE:  A  60  year-old  male  who  had undergone  left ocular  enucleation  for choroid
melanoma  20  years  ago  was  referred  to our  department  with  a  three  months  history  of diffuse  abdominal
pain,  fever,  weight  loss  and  massive  ascites.  Abdominal  ultrasonography  (US)  and  total  body  computed
tomography  (CT)  scan  were  performed  and  revealed  diffuse  liver  metastases,  associated  with peritoneal
carcinosis,  bilateral  adrenal  metastases  and  a large mass  in the  left  kidney  compatible  with  another  sec-
ondary  localization.  An ultrasound  guided  ﬁne  needle  agobiopsy  (FNA)  of  liver  lesions  was  performed  and
the pathological  ﬁndings  led to  the  diagnosis  of liver  metastasis  from  choroidal  melanoma.  The  patient
died  a few  weeks  later  for hepatic  failure.
DISCUSSION:  Currently,  there  is  no  consensus  regarding  the  optimal  follow-up  in  terms  of  screening
modality  or  time  interval  after  the  treatment  of the  primary  ocular  melanoma.
CONCLUSION:  Patients  with  gastrointestinal  symptoms  and  a history  of  choroidal  melanoma  should
be  investigated  for the  presence  of gastrointestinal  or liver  metastases,  although  the  original  primary
malignancy  was  diagnosed  years  before  the  patient’s  presentation.
© 2015  The  Authors.  Published  by  Elsevier  Ltd. on behalf  of Surgical  Associates  Ltd.  This  is an  open
he CCaccess  article  under  t
. Introduction
The incidence of malignant melanoma continues to increase
ramatically worldwide, at an overall rate of about 30% in the last
0 years [1]. In 2014, an estimated 76,100 new cases will be diag-
osed and about 9710 patients will die of melanoma in the United
tates [1].
Melanoma is increasing in men  more rapidly than any other
alignancy, and in women more rapidly than any other malignancy
xcept lung cancer (respectively 33% for men  and 23% for women)
1]. In Europe, the incidence varies in different areas, with higher
ates in the countries of Northern Europe (12–20 per 100,000 per
ear) than in the Mediterranean area (3–5 per 100,000 per year)
2].
∗ Corresponding author. Fax: +39 953782912.
E-mail address: schaky@hotmail.it (G. Piccolo).
ttp://dx.doi.org/10.1016/j.ijscr.2015.07.011
210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Assoc
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Choroidal melanoma is the most common primary intraocular
malignant tumour and the second most common type of primary
malignant melanoma in the body [3]. Biologically, cutaneous and
ocular melanoma may  be considered different, in terms of both
metastatic diffusion and metastatic latency [4]. The principal target
organ for metastasis of the ocular melanoma is the liver [4].
In contrast, cutaneous melanoma spreads primarily to lymph
nodes and soft tissues with only a lower incidence of hepatic diffu-
sion (14–20%) [5]. This distinctive behaviour is also sustained by a
different metastatic latency [4].
We report a case of metastatic choroidal melanoma after twenty
years from surgical removal.
2. Presentation of caseA 60 year-old male who  had undergone left ocular enucleation
for choroid melanoma 20 years ago was referred to our depart-
ment with a three months history of diffuse abdominal pain, fever,
weight loss (> 10 kg) and massive ascites. The histopathological
iates Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Multiple liver metastases by choroidal melanoma.
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gig. 2. A large mass involving the gallbladder and the anterior surface of the liver.
xamination of the enucleated left eye showed a mixed-cell-type
horoidal melanoma without intrascleral or vascular involvement.
he size of the melanoma was 10 mm in thickness and 13 mm in
iameter. Since then, the patient had been followed up regularly
y an ophthalmologist. The last follow-up at 15 years after eye
nucleation was negative for recurrence or metastatic diffusion.
t the admission, laboratory tests were normal, except for increase
A-125 marker. Abdominal ultrasonography (US) and total body
omputed tomography (CT) scan were performed and revealed dif-
use liver metastases in both lobes with a tendency to conﬂuence,
 large mass involving the gallbladder, associated with peritoneal
arcinosis, bilateral adrenal metastases and a large mass in the
eft kidney (5 cm of diameter) compatible with another secondary
ocalization (Figs. 1–3 ). EGDS and colonoscopy were performed in
rder to exclude other primitive malignant cancers. An ultrasound
uided ﬁne needle agobiopsy (FNA) of liver lesions was performedFig. 3. Peritoneal carcinosis with massive ascites.
and the pathological ﬁndings led to the diagnosis of liver metastasis
from choroidal melanoma (S-100 protein, vimentin, HMB-45 and
Melan A antibodies positive). Percutaneous evacuative paracente-
sis was  also performed and the cytology conﬁrmed the diagnosis.
A protocol of systemic chemotherapy was  started but the patient
died a few weeks later for hepatic failure.
3. Discussion
Visceral metastases represent an advanced stage of melanoma
and patients that develop metastatic disease continue to have a
poor prognosis with a 5-year survival of under 10% [1].
Liver metastases are usually associated with even worse out-
comes, with a median survival of few months [6]. Choroidal
melanoma is the second most common type of primary malignant
melanoma in the body and the liver is the principal target organ for
metastases [3].
Among patients that developing metastases, liver metastases
can be found in about 90% of the cases and often as a ﬁrst and only
metastatic site in approximately 40% of patients [3].
Metastatic melanoma to the gall bladder is extremely rare and is
associated with a very poor prognosis [7,8], delayed metastases to
brain, pancreas, adrenal glands and ovaries have also been reported
[9–14].
The correct treatment of hepatic metastases from ocular and
cutaneous melanoma is still object of debate. The recent devel-
opment of novel agents have demonstrated better efﬁcacy than
traditional chemotherapy. Ipilimumab, a monoclonal antibody
directed to the immune checkpoint receptor termed “cytotoxic
T lymphocyte antigen-4 (CTLA-4)” has been shown to improve
overall survival in patients with metastatic melanoma; similarly
vemurafenib (a selective B-Raf inhibitor) and trametinib (a selec-
tive inhibitor of MEK1/MEK2) were also demonstrated to improve
survival among patients with metastatic melanoma [15,16].
The other operative treatment options include hepatic resec-
tion, hepatic intra-arterial chemotherapy, chemoembolization and
hepatic perfusions [17].Nowadays in literature there aren’t randomized controlled stud-
ies to deﬁne the role of surgery in the treatment of hepatic
metastases from melanoma.
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In the era of the peri-operative chemotherapy and of the “tar-
get” therapy, the rules governing the treatment of the hepatic
metastasis are changed. Therefore in the contest of improving sur-
gical techniques, many surgeons have applied principles of hepatic
metastasectomy to the treatment of other types of non-colorectal
and non-neuroendocrine metastasis [3].
Although in colorectal cancer, it seems to be clear that hepatic
resection is the only possibility of treatment associated with long-
term survival and that all patients with resectable disease should be
offered hepatic resection, these recommendations still need to be
demonstrated for liver metastasis from melanoma. As reported by
a recently systematic review, radical resection of liver metastases
from melanoma appears to improve overall survival (OS) compared
with non-operative management (22–66 months vs 4–12 months),
but then, there is an high rate of tumor recurrences [3].
Three times as many, patients with ocular than cutaneous
melanoma underwent resection for liver metastases, these differ-
ences can be found in a different radical resection rate and in a
different recurrence site [3].
In literature there is the perception that liver metastases from
ocular melanoma seem to be more frequently multiples and it is
more difﬁcult to obtain an R0 resection.
Many patients with ocular metastatic melanoma achieve only
a R1-R2 resection after metastasectomy [3] and more likely recur
within the liver, whereas patients with a cutaneous primary tumor
more often develop extrahepatic involvement [18].
For the same reasons, the 5-year survival rate is also different
with a worse prognosis for patients with liver metastases from
cutaneous than ocular melanoma [18].
This distinctive behaviour is also sustained by a different
metastatic latency to the liver. In ocular melanoma synchronous
disease accounts for less than 1% of the cases [6], the majority
of patients will develop liver metastasis during the subsequent
follow-up period and some of these will present with metastatic
ocular melanoma to the liver several years after the treatment of
the primary tumor (Table 1).
4. Conclusion
Currently, there is no consensus regarding the optimal follow-
up, in terms of screening modality or time interval and there is no
convincing evidence that surveillance improves overall survival.
On the other hand, seems to be essential to draw up a correct
follow-up program after resection of ocular melanoma and after
resection of subsequent liver metastasis to achieve optimal out-
come. Therefore, patients with gastrointestinal symptoms and a
history of choroidal melanoma should be investigated for the pres-
ence of gastrointestinal or liver metastases, although the original
primary malignancy was  diagnosed years before the patient’s pre-
sentation.
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